Bouillon R, Muls E, De Moor P
J Clin Endocrinol Metab. 1980 Oct;51(4):793-7. doi: 10.1210/jcem-51-4-793.
The serum concentrations of parathyroid hormone, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 were measured in patients with untreated thyroid disorders. The serum concentration of parathyroid hormone was decreased in hyperthyroidism [20 +/- 10 mU/liter, (mean +/- SD); n =23; P < 0.01] and increased in hypothyroidism (53 +/- 17 mU/liter; n = 12; P < 0.001) compared to that in normal subjects (26 +/- 9 mU/liter; n = 81). The concentration of 25-hydroxyvitamin D3 was not altered, but the concentration of 1,25-dihydroxyvitamin D3 was significantly lower in the serum of hyperthyroid patients (28 +/- 11 ng/liter) than in the serum of normal subjects (42 +/- 13 ng/liter). On the contrary, an increased concentration of 1,25-dihydroxyvitamin D3 was observed in the serum of hypothyroid patients (73 +/- 28 ng/liter; P < 0.001 vs. normal subjects). The abnormal serum concentrations of 1,25-dihydroxyvitamin D3 in thyroid disorders cannot be explained by differences in serum binding because the serum vitamin D-binding protein was unaltered in hyperthyroid subjects and only slightly increased (+17%) in hypothyroid subjects. These changes in the serum concentration of 1,25-dihydroxyvitamin D3 are compatible with previous data on altered intestinal calcium absorption in thyroid disorders.
对未经治疗的甲状腺疾病患者测定了甲状旁腺激素、25-羟基维生素D3和1,25-二羟基维生素D3的血清浓度。与正常受试者（26±9 mU/升；n = 81）相比，甲状旁腺激素的血清浓度在甲状腺功能亢进症患者中降低[20±10 mU/升，（均值±标准差）；n = 23；P < 0.01]，而在甲状腺功能减退症患者中升高（53±17 mU/升；n = 12；P < 0.001）。25-羟基维生素D3的浓度未改变，但甲状腺功能亢进症患者血清中1,25-二羟基维生素D3的浓度（28±11 ng/升）显著低于正常受试者血清中的浓度（42±13 ng/升）。相反，在甲状腺功能减退症患者血清中观察到1,25-二羟基维生素D3的浓度升高（73±28 ng/升；与正常受试者相比P < 0.001）。甲状腺疾病中1,25-二羟基维生素D3的血清浓度异常无法用血清结合差异来解释，因为甲状腺功能亢进症患者血清维生素D结合蛋白未改变，而甲状腺功能减退症患者仅略有升高（+17%）。1,25-二羟基维生素D3血清浓度的这些变化与先前关于甲状腺疾病中肠道钙吸收改变的数据一致。
